Risk of squamous cell carcinoma in patients with hidradenitis suppurativa treated with anti-TNF-alpha-Results from a 12-year multicentric observational prospective study

Affiliations

¹ Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University and Královské Vinohrady University Hospital, Prague, Czech Republic.
² Department of Pharmacology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
³ Department of Medical Biophysics and Medical Informatics, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic.
⁴ Department of Dermatology and Venerology, University Hospital Motol, Prague, Czech Republic.

Observational Study

Alžběta Smetanová et al. J Eur Acad Dermatol Venereol. 2024 Sep.

. 2024 Sep;38(9):e807-e809.

doi: 10.1111/jdv.19916. Epub 2024 Feb 26.

¹ Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University and Královské Vinohrady University Hospital, Prague, Czech Republic.
² Department of Pharmacology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
³ Department of Medical Biophysics and Medical Informatics, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic.
⁴ Department of Dermatology and Venerology, University Hospital Motol, Prague, Czech Republic.

No abstract available

References

1. Jourabchi N, Fischer AH, Cimino‐Mathews A, Waters KM, Okoye GA. Squamous cell carcinoma complicating a chronic lesion of hidradenitis suppurativa: a case report and review of the literature. Int Wound J. 2017;14:435–438.
1. Lavogiez C, Delaporte E, Darras‐Vercambre S, Martin De Lassale E, Castillo C, Mirabel X, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology. 2010;220:147–153.
1. Cooper SD, Cowdrey MCE, Linos KD, Lefferts JA, Basic KK. Squamous cell carcinoma in hidradenitis suppurativa lesions following tumor necrosis factor α inhibitors. Cutis. 2021;107:E5–E7.
1. Kreher MA, Konda S, Noland MMB, Longo MI, Valdes‐Rodriguez R. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors. J Am Acad Dermatol. 2023;88:534–542.
1. Li Pomi F, Macca L, Motolese A, Ingrasciotta Y, Berretta M, Guarneri C. Neoplastic implications in patients suffering from hidradenitis suppurativa under systemic treatments. Biomedicine. 2021;9:1594.